• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Juventas reports data from phase I heart failure trial

Juventas reports data from phase I heart failure trial

January 30, 2012
CenterWatch Staff

Cleveland, Ohio-based Juventas Therapeutics, developing novel regenerative therapies for treating cardiovascular disease, has released the 12-month results from its phase I heart failure study of JVS-100.

JVS-100 encodes Stromal cell-Derived Factor 1 (SDF-1) and has been shown to repair damaged tissue through recruitment of circulating stem cells to the site of injury, prevention of ongoing cell death and restoration of blood flow.

The 17-person, open-label, dose-escalation study targeted New York Heart Association (NYHA) class III heart failure patients, who represent approximately a quarter of the six million heart failure patients in the U.S. and account for half of all heart failure hospital admissions. The clinical trial met its primary safety endpoint with no serious adverse events deemed drug related. 

Fifteen of the 17 patients in the trial survived to a year. Patients receiving target therapeutic doses demonstrated clinically significant improvements at 12 months in six-minute walk distance and the Minnesota Living with Heart Failure Questionnaire.  Nearly half of the patients improved a full NYHA class, with multiple patients improving two full classes.

"The patient population we treated in this trial has a true unmet clinical need and tends to have rapidly deteriorating quality of life," said Marc Penn, M.D., Ph.D, founder and chief medical officer for Juventas and director of cardiovascular research at the Summa Cardiovascular Institute at Summa Health System.  "To see clinical symptomatic benefits of this magnitude maintained from four to 12 months after JVS-100 treatment suggests we are inducing fundamental changes in the heart of treated patients.  We believe this is consistent with our understanding of the mechanisms associated with JVS-100 and warrants further investigation."

Based on these results, the company is preparing to enroll a placebo-controlled, randomized, double-blinded phase II heart-failure clinical trial in the U.S. to further define the efficacy of JVS-100.  Also, Juventas has received FDA clearance to enroll a phase IIa trial evaluating safety and efficacy of JVS-100 in patients with critical limb ischemia.  The CLI trial is enrolling patients in the U.S. and India.  In addition to safety, the trial will assess time to amputation and other efficacy endpoints and will begin enrollment in the first quarter of 2012.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing